GO:0051386 regulation of neurotrophin TRK receptor signaling pathway: Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051386 describes any process that modulates the frequency, rate or extent of the neurotrophin TRK receptor signaling pathway.
• Neurotrophins (NGF, BDNF, NT-3, NT-4) bind TRK receptors (TRKA, TRKB, TRKC) to control neuronal survival, differentiation, and plasticity.
• Regulation occurs at multiple levels: ligand availability, receptor trafficking, post-translational modifications, and feedback inhibitors such as SOCS2.
• Dysregulation of TRK signaling is implicated in cancers (e.g., gastric tumorigenesis via NGF) and pain disorders such as endometriosis.
• Structural studies reveal how antidepressants can modulate TRKB transmembrane signaling, highlighting therapeutic potential.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect causal roles of regulators in this pathway.
Description
The neurotrophin TRK receptor signaling pathway is a fundamental cascade that governs neuronal survival, development, and synaptic plasticity. It is initiated when neurotrophins such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) bind to their cognate TRK receptors (TRKA, TRKB, TRKC), triggering receptor dimerization, autophosphorylation, and downstream activation of MAPK, PI3K/AKT, and PLCγ pathways. This pathway is tightly regulated to ensure appropriate responses in the nervous system and beyond. GO:0051386, regulation of neurotrophin TRK receptor signaling pathway, encompasses all processes that modulate the frequency, rate, or extent of this signaling cascade. Understanding these regulatory mechanisms is critical because their disruption contributes to neurodegeneration, cancer, and chronic pain. Moreover, recent structural and pharmacological studies have revealed that TRK signaling can be modulated by small molecules, offering new therapeutic avenues. Researchers investigating this term need robust experimental models to identify and validate regulatory components, making CRISPR-based approaches indispensable.
regulation of neurotrophin TRK receptor signaling pathway At A Glance
| GO ID | GO:0051386 |
|---|---|
| GO term | regulation of neurotrophin TRK receptor signaling pathway |
| Ontology | biological_process |
| Synonym | regulation of nerve growth factor receptor signaling pathway; regulation of NGF receptor signaling pathway |
| Major function | Modulates the frequency, rate or extent of neurotrophin TRK receptor signaling |
| Related pathways | Neurotrophin signaling, MAPK cascade, PI3K/AKT signaling, PLCγ signaling |
| Key regulators | SOCS2, receptor trafficking proteins, phosphatases, kinases |
| Disease relevance | Cancer, neuropathic pain, neurodegeneration, endometriosis |
What Is GO:0051386?
GO:0051386 is a biological process term defined as any process that modulates the frequency, rate or extent of the neurotrophin TRK receptor signaling pathway. In other words, it includes all molecular events that fine-tune the strength, duration, or location of signals emanating from activated TRK receptors. This regulation can occur through changes in ligand availability, receptor expression, trafficking, post-translational modifications, or feedback inhibition by intracellular proteins.
Why Is regulation of neurotrophin TRK receptor signaling pathway Important in Cell Biology?
Regulation of neurotrophin TRK receptor signaling is crucial for normal nervous system function and for preventing pathological conditions. Dysregulated TRK signaling is linked to tumorigenesis, chronic pain, and neurodegenerative disorders. Understanding how this pathway is controlled at the molecular level can reveal therapeutic targets and biomarkers. For example, SOCS2 has emerged as a negative regulator of TRK signaling, and its manipulation could influence neuronal survival or cancer progression. Additionally, structural insights into TRKB activation by antidepressants suggest that pharmacological modulation of TRK signaling is feasible. Therefore, studying GO:0051386 is essential for both basic neurobiology and translational medicine.
• Controls neuronal survival and differentiation during development.
• Regulates synaptic plasticity and memory formation.
• Its dysregulation contributes to gastric cancer progression.
• Involved in endometriosis-associated pain.
• SOCS2 acts as a negative regulator, providing a feedback mechanism.
• Receptor trafficking modulates signal duration and location.
• Antidepressants can directly activate TRKB, linking mood disorders to TRK signaling.
• Potential target for neuroprotective therapies.
• Key to understanding neurotrophin-based cancer therapies.
• CRISPR screens can identify novel regulators of this pathway.
What Happens During regulation of neurotrophin TRK receptor signaling pathway?
Ligand Binding and Receptor Activation
In simple terms: Neurotrophins bind to TRK receptors, causing them to pair up and activate.
Neurotrophins (NGF, BDNF, NT-3, NT-4) bind with high affinity to their specific TRK receptors (TRKA, TRKB, TRKC), inducing receptor dimerization and autophosphorylation of tyrosine residues in the intracellular domain. This activation is the first step that can be regulated by ligand availability, receptor expression levels, and alternative splicing.
Intracellular Signaling Cascades
In simple terms: Activated TRK receptors turn on multiple signaling pathways inside the cell.
Phosphorylated TRK receptors recruit adaptor proteins such as SHC, GRB2, and PLCγ, leading to activation of the MAPK/ERK, PI3K/AKT, and PLCγ pathways. These cascades promote neuronal survival, differentiation, and synaptic plasticity. Regulation can occur through phosphatases that dephosphorylate TRK receptors or through inhibitors that block downstream effectors.
Receptor Trafficking and Degradation
In simple terms: After activation, TRK receptors are moved around or broken down to control signal duration.
Activated TRK receptors are internalized into endosomes, where they can continue signaling or be sorted for degradation. This trafficking is tightly regulated and determines whether signals are transient or sustained. Proteins involved in endocytosis and vesicular transport modulate this process, thereby regulating the pathway.
Feedback Inhibition by SOCS2
In simple terms: SOCS2 acts as a brake on TRK signaling to prevent overactivation.
Suppressor of cytokine signaling 2 (SOCS2) has been identified as a negative regulator of TRK signaling. It binds to activated TRK receptors and promotes their ubiquitination and degradation, thereby attenuating the signal. This feedback mechanism is crucial for preventing excessive neurotrophic signaling, which could lead to cancer or other pathologies.
Modulation by Antidepressants and Small Molecules
In simple terms: Certain drugs can directly influence TRK receptor activity.
Recent structural studies have shown that antidepressants like fluoxetine can bind to the transmembrane domain of TRKB and activate it, independent of neurotrophins. This reveals an additional layer of regulation and suggests that small molecules can modulate TRK signaling for therapeutic benefit.
Key Genes Involved in GO:0051386 regulation of neurotrophin TRK receptor signaling pathway
The following genes and proteins are key players in the regulation of neurotrophin TRK receptor signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NGF | Neurotrophin ligand for TRKA | Promotes neuronal survival; implicated in pain and cancer |
| BDNF | Neurotrophin ligand for TRKB | Regulates synaptic plasticity and mood |
| NTF3 | Neurotrophin ligand for TRKC | Controls proprioceptive neuron development |
| NTF4 | Neurotrophin ligand for TRKB | Modulates visual system development |
| NTRK1 | TRKA receptor tyrosine kinase | Mediates NGF signaling; mutated in congenital insensitivity to pain |
| NTRK2 | TRKB receptor tyrosine kinase | Mediates BDNF signaling; target of antidepressants |
| NTRK3 | TRKC receptor tyrosine kinase | Mediates NT-3 signaling; involved in medulloblastoma |
| SOCS2 | Negative regulator of TRK signaling | Promotes TRK degradation; potential tumor suppressor |
| SHC1 | Adaptor protein | Links TRK to MAPK pathway |
| GRB2 | Adaptor protein | Activates RAS-MAPK cascade |
| PLCG1 | Phospholipase C gamma 1 | Produces IP3 and DAG; regulates calcium signaling |
| PIK3CA | PI3K catalytic subunit | Activates AKT survival pathway |
| AKT1 | Serine/threonine kinase | Promotes cell survival downstream of PI3K |
| MAPK1 | ERK2 kinase | Transduces proliferative and differentiation signals |
| RAB5A | Early endosome marker | Regulates TRK endocytosis and signaling |
| UBB | Ubiquitin | Tags TRK receptors for degradation |
| PTPN11 | SHP-2 phosphatase | Modulates TRK signaling by dephosphorylation |
How Is regulation of neurotrophin TRK receptor signaling pathway Regulated?
The regulation of neurotrophin TRK receptor signaling is achieved through multiple mechanisms. Ligand availability is controlled by neurotrophin expression, secretion, and cleavage. Receptor levels are modulated by transcription, alternative splicing, and trafficking. Post-translational modifications such as phosphorylation, ubiquitination, and glycosylation directly affect receptor activity and stability. Negative feedback loops involving SOCS2 and phosphatases ensure signal termination. Additionally, cross-talk with other signaling pathways (e.g., cholinergic signaling in gastric cancer) can influence TRK pathway output.
regulation of neurotrophin TRK receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NGF | Gastric cancer, endometriosis pain | NGF knockout or overexpression in mouse models |
| NTRK2 | Depression, neurodegeneration | TRKB point mutation or knock-in mice |
| SOCS2 | Cancer, neuroprotection | SOCS2 knockout or overexpression cell lines |
| NTRK1 | Congenital insensitivity to pain | TRKA knockout or point mutation models |
| NTRK3 | Medulloblastoma | TRKC knockout or overexpression models |
Cancer
Dysregulated TRK signaling contributes to tumorigenesis. NGF promotes gastric tumorigenesis through aberrant cholinergic signaling, and TRK fusions or overexpression are oncogenic in various cancers. SOCS2, as a negative regulator, may act as a tumor suppressor by attenuating TRK signals. Targeting TRK signaling is a therapeutic strategy in cancers with NTRK alterations.
Chronic Pain and Endometriosis
NGF signaling through TRKA is a key mediator of pain. In endometriosis, targeting NGF but not BDNF or VEGFR1 reduces pain in mouse models. This highlights the importance of specific TRK pathway components in pain disorders and the potential of selective inhibitors.
Neurodegeneration and Mood Disorders
Reduced BDNF-TRKB signaling is associated with depression and neurodegenerative diseases. Antidepressants can directly activate TRKB, suggesting that enhancing TRK signaling may have therapeutic benefits. Conversely, excessive TRK signaling may contribute to epilepsy or neuropathic pain.
From regulation of neurotrophin TRK receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate TRK signaling? | Knockout of gene X in neuronal cell lines (e.g., PC12) |
| Does a specific mutation in TRK affect signaling? | Point mutation knock-in of NTRK2 in mice |
| How does a regulator interact with TRK? | Tagged knock-in of SOCS2 for co-IP |
| Does overexpression of a ligand enhance signaling? | Overexpression of NGF in cell culture |
| What is the effect of a regulator on neuronal survival? | Knockout of candidate gene in primary neurons |
| Can a drug modulate TRK signaling? | Point mutation of TRKB transmembrane domain |
How to Study the regulation of neurotrophin TRK receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on TRK signaling | Identify negative regulators like SOCS2 |
| Phosphoproteomics | Phosphorylation changes | Map signaling cascades downstream of TRK |
| Live-cell imaging | Receptor trafficking and localization | Study endosomal signaling |
| RNA-seq | Transcriptional changes | Identify feedback regulators |
| Co-immunoprecipitation | Protein-protein interactions | Validate SOCS2-TRK binding |
| Western blot | Protein expression and phosphorylation | Confirm knockout efficiency |
| Luciferase reporter assay | Pathway activity | High-throughput screening |
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify novel regulators of TRK signaling. Cells expressing a TRK-dependent reporter (e.g., luciferase under MAPK response element) are transduced with a CRISPR library, and regulators are identified by changes in reporter activity.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics can quantify changes in TRK receptor phosphorylation and downstream signaling upon genetic perturbation. This method reveals dynamic regulation of the pathway.
Live-Cell Imaging
Fluorescently tagged TRK receptors and endosomal markers allow real-time visualization of receptor trafficking and signaling endosome formation. This is critical for understanding regulation by trafficking.
Transcriptomics
RNA-seq after knockout or overexpression of candidate regulators can reveal transcriptional feedback and identify downstream targets of TRK signaling.
How CRISPR Can Be Used to Study GO:0051386 regulation of neurotrophin TRK receptor signaling pathway
Knockout
CRISPR knockout of candidate regulators (e.g., SOCS2) in neuronal cell lines or primary neurons can determine their role in modulating TRK signaling. Loss of a negative regulator like SOCS2 may enhance and prolong TRK signaling, affecting survival or differentiation.
Point Mutation
Introducing specific point mutations in TRK receptors (e.g., in the kinase domain or transmembrane domain) can dissect structure-function relationships. For example, mutations that prevent antidepressant binding can test the direct activation mechanism.
Knock-in
Knock-in of tagged versions of TRK receptors or regulators (e.g., HA-tagged SOCS2) allows for affinity purification and proteomic analysis of interacting partners, revealing new regulatory complexes.
Overexpression
Overexpression of neurotrophins or TRK receptors using CRISPR activation (CRISPRa) or lentiviral vectors can amplify signaling to study downstream effects and identify saturation points of regulation.
How EDITGENE Supports regulation of neurotrophin TRK receptor signaling pathway Research
Researchers studying regulation of neurotrophin TRK receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in modulating the pathway. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of regulators in this pathway.
Contact EDITGENE today to design your custom CRISPR model for regulation of neurotrophin TRK receptor signaling pathway research.
Frequently Asked Questions About regulation of neurotrophin TRK receptor signaling pathway
What is GO:0051386?
GO:0051386 is a Gene Ontology term for any process that modulates the frequency, rate or extent of the neurotrophin TRK receptor signaling pathway.
What genes are involved in regulation of neurotrophin TRK receptor signaling?
Key genes include NGF, BDNF, NTRK1, NTRK2, NTRK3, and SOCS2, among others.
How is TRK signaling regulated?
It is regulated at multiple levels: ligand availability, receptor trafficking, post-translational modifications, and feedback inhibitors like SOCS2.
What diseases are associated with dysregulated TRK signaling?
Cancers such as gastric cancer, chronic pain conditions like endometriosis, and neurodegenerative disorders.
What is the role of SOCS2 in TRK signaling?
SOCS2 acts as a negative regulator by promoting ubiquitination and degradation of activated TRK receptors.
Can antidepressants modulate TRK signaling?
Yes, structural studies show that antidepressants like fluoxetine can directly bind and activate TRKB.
How can CRISPR help study TRK signaling regulation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of regulators in this pathway.
What methods are used to study TRK signaling?
Common methods include phosphoproteomics, live-cell imaging, RNA-seq, and CRISPR screens.
Is NGF involved in pain?
Yes, NGF signaling through TRKA mediates pain, and targeting NGF reduces endometriosis-associated pain in mice.
What cell models are available for TRK research?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for genes in the TRK pathway.
Conclusion
GO:0051386, regulation of neurotrophin TRK receptor signaling pathway, is a critical biological process that ensures proper neuronal function and prevents disease. Its multifaceted regulation involves ligands, receptors, trafficking proteins, and feedback inhibitors. Dysregulation contributes to cancer, pain, and neurodegeneration, making it a prime target for therapeutic intervention. CRISPR-based models are indispensable for dissecting these regulatory mechanisms and validating new drug targets.
References
- 1. Huang EJ et al.. 2003. Trk receptors: roles in neuronal signal transduction.. Annu Rev Biochem 72:609-42 PMID: 12676795
- 2. Huang EJ et al.. 2001. Neurotrophins: roles in neuronal development and function.. Annu Rev Neurosci 24:677-736 PMID: 11520916
- 3. Uren RT et al.. 2014. Regulation of neurotrophin receptor (Trk) signaling: suppressor of cytokine signaling 2 (SOCS2) is a new player.. Front Mol Neurosci 7:39 PMID: 24860421
- 4. Hayakawa Y et al.. 2017. Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling.. Cancer Cell 31(1):21-34 PMID: 27989802
- 5. Reichardt LF. 2006. Neurotrophin-regulated signalling pathways.. Philos Trans R Soc Lond B Biol Sci 361(1473):1545-64 PMID: 16939974
- 6. Kot EF et al.. 2024. Structural basis for the transmembrane signaling and antidepressant-induced activation of the receptor tyrosine kinase TrkB.. Nat Commun 15(1):9316 PMID: 39472452
- 7. Zaninelli TH et al.. 2025. Targeting NGF but not VEGFR1 or BDNF signaling reduces endometriosis-associated pain in mice.. J Adv Res 73:593-605 PMID: 39142441
- 8. Scott-Solomon E et al.. 2018. Mechanisms of neurotrophin trafficking via Trk receptors.. Mol Cell Neurosci 91:25-33 PMID: 29596897
